Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.94
ELGX's Cash to Debt is ranked lower than
58% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. ELGX: 0.94 )
Ranked among companies with meaningful Cash to Debt only.
ELGX' s Cash to Debt Range Over the Past 10 Years
Min: 0.94  Med: 10000.00 Max: No Debt
Current: 0.94
Equity to Asset 0.43
ELGX's Equity to Asset is ranked lower than
78% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. ELGX: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
ELGX' s Equity to Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.85 Max: 0.96
Current: 0.43
0.41
0.96
F-Score: 1
Z-Score: 1.06
M-Score: -2.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -27.59
ELGX's Operating margin (%) is ranked lower than
77% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. ELGX: -27.59 )
Ranked among companies with meaningful Operating margin (%) only.
ELGX' s Operating margin (%) Range Over the Past 10 Years
Min: -225.97  Med: -21.37 Max: -4.47
Current: -27.59
-225.97
-4.47
Net-margin (%) -32.57
ELGX's Net-margin (%) is ranked lower than
77% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. ELGX: -32.57 )
Ranked among companies with meaningful Net-margin (%) only.
ELGX' s Net-margin (%) Range Over the Past 10 Years
Min: -217.37  Med: -32.81 Max: 15.84
Current: -32.57
-217.37
15.84
ROE (%) -43.07
ELGX's ROE (%) is ranked lower than
85% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. ELGX: -43.07 )
Ranked among companies with meaningful ROE (%) only.
ELGX' s ROE (%) Range Over the Past 10 Years
Min: -41.83  Med: -35.38 Max: 15.58
Current: -43.07
-41.83
15.58
ROA (%) -20.75
ELGX's ROA (%) is ranked lower than
76% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. ELGX: -20.75 )
Ranked among companies with meaningful ROA (%) only.
ELGX' s ROA (%) Range Over the Past 10 Years
Min: -34.87  Med: -22.97 Max: 11.48
Current: -20.75
-34.87
11.48
ROC (Joel Greenblatt) (%) -76.51
ELGX's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.36 vs. ELGX: -76.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ELGX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -250.89  Med: -108.88 Max: -21.18
Current: -76.51
-250.89
-21.18
Revenue Growth (3Y)(%) 15.40
ELGX's Revenue Growth (3Y)(%) is ranked higher than
86% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ELGX: 15.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ELGX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.8  Med: 15.25 Max: 66.8
Current: 15.4
-41.8
66.8
EBITDA Growth (3Y)(%) -7.80
ELGX's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. ELGX: -7.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ELGX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50  Med: -7.25 Max: 73.8
Current: -7.8
-50
73.8
EPS Growth (3Y)(%) -0.70
ELGX's EPS Growth (3Y)(%) is ranked lower than
60% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. ELGX: -0.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ELGX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.2  Med: 1.75 Max: 122.9
Current: -0.7
-50.2
122.9
» ELGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ELGX Guru Trades in Q4 2014

Steven Cohen Sold Out
Pioneer Investments 689,134 sh (-6.69%)
» More
Q1 2015

ELGX Guru Trades in Q1 2015

Jim Simons 81,400 sh (New)
Pioneer Investments 598,774 sh (-13.11%)
» More
Q2 2015

ELGX Guru Trades in Q2 2015

Jim Simons 165,598 sh (+103.44%)
Pioneer Investments 652,398 sh (+8.96%)
» More
Q3 2015

ELGX Guru Trades in Q3 2015

Paul Tudor Jones 20,341 sh (New)
Steven Cohen 573,100 sh (New)
Pioneer Investments 801,248 sh (+22.82%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Endologix Inc

Meridian Funds Comments on Endologix Inc - Dec 17, 2014

Endologix (ELGX) is a medical device company with products that treat aortic abdominal aneurisms (AAA). Recently the company experienced a decline in sales growth after the conclusion of a clinical trial rollout. We believed the revenue issue was temporary and were very excited about a new product called Nellix that has the potential to more than double Endologix’s market share in AAA procedures. During the quarter, share performance disappointed after the company disclosed that sales would again miss expectations, this time due to an intensifying competitive environment. While management outlined an aggressive response, including product enhancements intended to further improve upon the lowest complication rate in the AAA industry, we have reduced our position until we can gain greater clarity on how effective these efforts will be in the market.

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/B 4.73
ELGX's P/B is ranked lower than
86% of the 255 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. ELGX: 4.73 )
Ranked among companies with meaningful P/B only.
ELGX' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 5.31 Max: 14.14
Current: 4.73
1.69
14.14
P/S 3.08
ELGX's P/S is ranked lower than
68% of the 255 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.28 vs. ELGX: 3.08 )
Ranked among companies with meaningful P/S only.
ELGX' s P/S Range Over the Past 10 Years
Min: 1.14  Med: 6.75 Max: 42.27
Current: 3.08
1.14
42.27
Current Ratio 4.01
ELGX's Current Ratio is ranked higher than
72% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. ELGX: 4.01 )
Ranked among companies with meaningful Current Ratio only.
ELGX' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 5.97 Max: 20.25
Current: 4.01
2.15
20.25
Quick Ratio 3.00
ELGX's Quick Ratio is ranked higher than
68% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. ELGX: 3.00 )
Ranked among companies with meaningful Quick Ratio only.
ELGX' s Quick Ratio Range Over the Past 10 Years
Min: 2  Med: 4.66 Max: 19.04
Current: 3
2
19.04
Days Inventory 252.49
ELGX's Days Inventory is ranked lower than
86% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.52 vs. ELGX: 252.49 )
Ranked among companies with meaningful Days Inventory only.
ELGX' s Days Inventory Range Over the Past 10 Years
Min: 168.66  Med: 259.35 Max: 537.05
Current: 252.49
168.66
537.05
Days Sales Outstanding 64.69
ELGX's Days Sales Outstanding is ranked lower than
51% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 64.05 vs. ELGX: 64.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.06  Med: 65.43 Max: 77.86
Current: 64.69
58.06
77.86
Days Payable 110.01
ELGX's Days Payable is ranked higher than
81% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. ELGX: 110.01 )
Ranked among companies with meaningful Days Payable only.
ELGX' s Days Payable Range Over the Past 10 Years
Min: 69.82  Med: 135.84 Max: 425.72
Current: 110.01
69.82
425.72

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 229.67
ELGX's Price/Net Current Asset Value is ranked lower than
88% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.33 vs. ELGX: 229.67 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ELGX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.92  Med: 7.00 Max: 574
Current: 229.67
0.92
574
Price/Tangible Book 16.80
ELGX's Price/Tangible Book is ranked lower than
86% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.59 vs. ELGX: 16.80 )
Ranked among companies with meaningful Price/Tangible Book only.
ELGX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.81  Med: 6.33 Max: 114.8
Current: 16.8
0.81
114.8
Price/Median PS Value 0.46
ELGX's Price/Median PS Value is ranked higher than
96% of the 255 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.05 vs. ELGX: 0.46 )
Ranked among companies with meaningful Price/Median PS Value only.
ELGX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1.02 Max: 7.21
Current: 0.46
0.2
7.21
Earnings Yield (Greenblatt) (%) -9.24
ELGX's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. ELGX: -9.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ELGX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -9.56  Med: 0.00 Max: 0
Current: -9.24
-9.56
0

More Statistics

Revenue(Mil) $153
EPS $ -0.73
Beta0.85
Short Percentage of Float17.02%
52-Week Range $6.57 - 18.07
Shares Outstanding(Mil)67.79

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 155 173 195 219
EPS($) -0.59 -0.53 -0.49 -0.26
EPS without NRI($) -0.59 -0.53 -0.49 -0.26

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RM1.Germany,
Endologix Inc was incorporated in California on March 16, 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells medical devices for the treatment of abdominal aortic aneurysms (AAA). Its main products are intended for the treatment of AAA through minimally-invasive endovascular repair (EVAR) or endovascular sealing ('EVAS'), solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The Company's EVAR products consist of: a cobalt chromium alloy stent covered by polytetrafluoroethylene graft material; and an accompanying delivery system. The Company's EVAS product consists of: bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. All of its products are manufactured, assembled, and packaged at its 60,000 square foot leased facilities in Irvine, California and markets and sells its products in the U.S. and in 11 Western European countries through a direct sales force and network of agents. The Company sells EVAR products through exclusive independent distributors or agents in 14 other European countries, Japan, 9 countries in South America, New Zealand and Mexico. Its main competitors include: Medtronic, Inc., W.L. Gore Inc., and Cook Medical Products, Inc., and new market entrants, TrvVascular, Inc. and Lombard Medical Technologies. The Company is subject to additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for ELGX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Endologix Inc Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 
Endologix Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Endologix Inc Reports Operating Results (10-Q) Jul 30 2010 
Weekly CEO Sells Highlight: Cisco Systems Inc, AmerisourceBergen Corp, PAETEC HOLDING CORP, Endologi May 22 2010 
Endologix Inc (ELGX) CEO John D Mcdermott sells 225,000 Shares May 17 2010 
Endologix Inc Reports Operating Results (10-Q) May 10 2010 

More From Other Websites
Profitable Ideas in Untold Names -- TransEnterix, Endologix, Mindray Medical Intl., and Hill-Rom... Feb 09 2016
ENDOLOGIX INC /DE/ Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Change in... Feb 03 2016
Endologix, Inc. and TriVascular Technologies, Inc. Complete Merger Feb 03 2016
Endologix to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 11 2016
4 Stocks Under $10 to Trade for Big Breakouts Jan 06 2016
Endologix AFX(R) Endovascular AAA System Receives Shonin Approval for Marketing in Japan Jan 04 2016
Endologix to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Endologix, Inc. breached its 50 day moving average in a Bearish Manner : January 1, 2016 Jan 01 2016
4 Stocks Under $10 Making Big Moves Dec 23 2015
Endologix AFX(R) Endovascular AAA System Receives Shonin Approval for Marketing in Japan Dec 10 2015
ENDOLOGIX INC /DE/ Financials Dec 08 2015
Hedge Funds Are Buying Endologix, Inc. (ELGX) Dec 02 2015
4 Under-$10 Stocks Making Big Moves Higher Nov 29 2015
Hedge Funds Are Selling Greenhill & Co., Inc. (GHL) Nov 28 2015
Endologix, Express, Rockwell Automation Lead After-Hours Movers To Close Holiday Week Nov 27 2015
Here is What Hedge Funds Think About ImmunoGen, Inc. (IMGN) Nov 25 2015
Endologix to Participate in Two Investor Conferences in December Nov 24 2015
Endologix to Participate in Two Investor Conferences in December Nov 24 2015
Positive Nellix Clinical Data From the EVAS FORWARD Global Registry Presented at 2015 VEITH... Nov 19 2015
Endologix, Inc. and TriVascular Technologies, Inc. Announce Early Termination of Hart-Scott-Rodino... Nov 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK